Figure 4.
In vivo activity of KDM1A inhibitors on high Zeb2 expressing murine and human T-ALL. (A) Kaplan-Meier survival curves of NSG mice injected with 2 P53/R26-Zeb2tg/tg murine tumor lines with and without 3 weeks of GSK2879552 administration (1.5 mg/kg bodyweight). (B) Percentage of hCD45+ T-ALL cells in peripheral blood of NSG mice xenotransplanted with LOUCY human T-ALL cells, before and after 18 days of GSK2879552 administration (1.5 mg/kg bodyweight) vs DMSO. (C) Percent spleen weight after 18 days of KDM1A inhibition (1.5 mg GSK2879552/kg bodyweight) vs DMSO. (D) Percentage of hCD45+ T-ALL cells in peripheral blood of NSG mice xenotransplanted with PEER human T-ALL cells, before and after 17 days of GSK2879552 administration (1.5 mg/kg bodyweight) vs DMSO. (E) Percent spleen weight after 17 days of KDM1A inhibitor administration (1.5 mg/kg bodyweight) vs DMSO.

In vivo activity of KDM1A inhibitors on high Zeb2 expressing murine and human T-ALL. (A) Kaplan-Meier survival curves of NSG mice injected with 2 P53/R26-Zeb2tg/tg murine tumor lines with and without 3 weeks of GSK2879552 administration (1.5 mg/kg bodyweight). (B) Percentage of hCD45+ T-ALL cells in peripheral blood of NSG mice xenotransplanted with LOUCY human T-ALL cells, before and after 18 days of GSK2879552 administration (1.5 mg/kg bodyweight) vs DMSO. (C) Percent spleen weight after 18 days of KDM1A inhibition (1.5 mg GSK2879552/kg bodyweight) vs DMSO. (D) Percentage of hCD45+ T-ALL cells in peripheral blood of NSG mice xenotransplanted with PEER human T-ALL cells, before and after 17 days of GSK2879552 administration (1.5 mg/kg bodyweight) vs DMSO. (E) Percent spleen weight after 17 days of KDM1A inhibitor administration (1.5 mg/kg bodyweight) vs DMSO.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal